Chemed Short Interest Jumps 20% Before Q3 Print

Chemed Corporation reports third-quarter results today, with short sellers having quietly built their largest position of the past month in the days immediately before the release.

Short interest climbed 20% over the past week to nearly 695,000 shares, or about 4.9% of the free float, the highest level in at least a month. The move is 1.6 standard deviations above Chemed's typical weekly change, making it one of the more decisive pre-earnings short builds the stock has seen recently. Cost to borrow has also moved, rising 53% over the week to 0.45%, though it remains low in absolute terms. Availability is ample, with roughly 10 million shares available to lend, so the borrow market is not constrained. The options market offers little additional color: the put/call ratio of 1.05 is essentially flat with its 20-day average, and the z-score of 0.32 is unremarkable. Chemed's shares are down 1.4% on the week, against a median gain of roughly 3.5% for its closest peers, with Ensign Group up 2.2% and Addus HomeCare up 5.2% over the same period.

The debate over Chemed centers on the divergence between its two business segments. The bull case rests on VITAS, the company's hospice division and the largest in the country, where long-term demographic demand remains strong and management has guided for a meaningful recovery in 2026. Oppenheimer raised its target to $590 after the Q2 print, and UBS initiated coverage in September with a Buy rating and a $650 target, placing both firmly above the current price of around $509. The bear case focuses on Roto-Rooter, where margin pressure has been concrete: adjusted EBITDA margin fell 520 basis points, and lead generation declined year on year. RBC Capital, which rates the stock Sector Perform at $548, and Bank of America, which holds a Neutral with a $510 target, reflect a more cautious read that the plumbing-services business is facing a structural rather than cyclical drag. The consensus sits at Buy, but with only two firms on that side, it is a thin majority.

Insider activity over the past 90 days has been one-directional. CEO Kevin McNamara sold 2,000 shares on September 28 for roughly $1.03 million, his second open-market sale of the quarter, following identical 2,000-share sales in August. Those are discretionary transactions with no 10b5-1 plan attached. EVP Spencer Lee exercised options and then sold shares in a same-day sequence on September 30, which is a compensation mechanic rather than a conviction signal. Net insider activity over the 90-day window amounts to roughly 9,200 shares sold for approximately $4.8 million in proceeds. That is a modest figure relative to the company's $6.6 billion market cap, but the CEO's repeated discretionary sales into strength are worth noting as context for today's print.

Wikipedia views for Chemed have spiked sharply in the days before the release, with a retail attention z-score of 6.0 against its own 90-day history, reflecting unusually elevated interest in the company. The Q2 print last July produced a 3.3% one-day gain and a 5.6% five-day gain, the most recent reaction data available. Today's results will test whether VITAS's recovery trajectory is materializing at the pace analysts priced in after the Q2 beat, and whether Roto-Rooter's margin erosion has stabilized or deepened.